|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ¹ú¹«µ§¸®´Ï¸àÆ® 40mL    
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
             |  
            
                
                
                
                      | 
                    Á¦Ç°º° ¿¬·É±Ý±â °í½Ã | 
                 
                 
                 | 
             
             |  
            
                
                    
                    
                        | ¼ººÐ¸í | 
                        ¼ººÐÄÚµå | 
                        ƯÁ¤¿¬·É | 
                        °í½Ã¹øÈ£ | 
                        °í½ÃÀÏÀÚ | 
                        ºñ°í | 
                     
               
                    
                        | enoxolone | 
                        E49600CLQ | 
                        30 °³¿ù ÀÌÇÏ | 
                        20250046 | 
                        2025-07-14 | 
                        ¼Ò¾Æ¿¡¼ °æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖÀ½ | 
                     
                 
                     
                 | 
             
            
              
            
             |  
            
                
                
                
                      | 
                    Á¦Ç°º° ÀӺαݱ⠰í½Ã | 
                 
                 
                 | 
             
             |  
            
                | 
                 1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ 
                
                
                    | ¼ººÐ¸í | 
                    ¼ººÐÄÚµå | 
                    ±Ý±âµî±Þ | 
                    °í½Ã¹øÈ£ | 
                    °í½ÃÀÏÀÚ | 
                    ºñ°í | 
                 
                
                    | Crotamiton | 
                    E49600CLQ | 
                    2 | 
                    20200130 | 
                    20201228 | 
                    ÀӺο¡ ´ëÇÑ ¾ÈÀü¼º ¹ÌÈ®¸³, ÀӺο¡°Ô ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÃÄ ±¤¹üÀ§ÇÏ°Ô »ç¿ëÇÏÁö ¸» °Í | 
                 
                 
                
                 | 
                                                                                          
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        641700521  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
                    [ºñ±Þ¿©]
                
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ƯÀÌÇÑ ¹æÇâÀÌ ÀÖ´Â Åõ¸íÇÑ ¹«»ö-´ãȲ»öÀÎ ¾×»óÀÇ ¸®´Ï¸àÆ®Á¦  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    40mL/º´ | 
   
  
  
  
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      E49600CLQ  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
  
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ±â¹Ð¿ë±â, ½Ç¿Â(1~30¡É)º¸°ü | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      ½ÀÁø, ÇǺο°, ¶¡¶ì, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο°, °¡·Á¿ò, ¹ú·¹¹°¸°µ¥, µÎµå·¯±â
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      1ÀÏ ¼öȸ(¿©·¯ Â÷·Ê) ȯºÎ(ÁúȯºÎÀ§)¿¡ Àû´ç·®À» ¹Ù¸¥´Ù.     
      	    
     | 
   
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      30°³¿ù ÀÌÇÏÀÇ À¯¾Æ
     | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    1) Áö±Ý±îÁö ¾àÀ̳ª ÈÀåǰ µî¿¡ ÀÇÇÑ ¾Ë·¹¸£±âÁõ»ó(¿¹¸¦ µé¸é ¹ßÁø¤ý¹ßÀû(ÃæÇ÷µÇ¾î ºÓ¾îÁü), °¡·Á¿ò, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο° µî)ÀÌ ³ªÅ¸³ ÀûÀÌ Àִ ȯÀÚ 
2) º»ÀÎ ¶Ç´Â °¡Á·ÀÌ ¾Ë·¹¸£±â üÁúÀΠȯÀÚ 
3) ½ÀÀ±(½À±â Âü)À̳ª ¹Ì¶õ(Áþ¹«¸§)ÀÌ ½ÉÇÑ È¯ÀÚ 
4) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ 
5) ¼Ò¾Æ(°æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù)
 | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ÀÎÇØ ¹ßÁø¤ý¹ßÀû(ÃæÇ÷µÇ¾î ºÓ¾îÁü), °¡·Á¿ò, ºÎÁ¾(ºÎ±â) µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    1) Á¤ÇØÁø ¿ë¹ý¤ý¿ë·®À» Àß ÁöŲ´Ù. 
2) ¼Ò¾Æ¿¡°Ô »ç¿ëÇÒ °æ¿ì¿¡´Â º¸È£ÀÚÀÇ Áöµµ¤ý°¨µ¶ ÇÏ¿¡ »ç¿ëÇÑ´Ù. 
3) 5¢¦6Àϰ£ Åõ¿© ÈÄ¿¡µµ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
 | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
   
    | Àû¿ë»óÀÇ ÁÖÀÇ | 
    1) ÀÌ ¾àÀº ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÏ°í ³»º¹ÇÏÁö ¾Ê´Â´Ù. 
2) ´«¿¡ µé¾î°¡Áö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. ¸¸ÀÏ ´«¿¡ µé¾î°£ °æ¿ì¿¡´Â Áï½Ã ¹°·Î ¾Ä´Â´Ù. Áõ»óÀÌ ½ÉÇÒ °æ¿ì¿¡´Â ¾È°úÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ´Â´Ù.
 | 
   
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    1) ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù. 
2) Á÷»çÀϱ¤À» ÇÇÇÏ°í µÉ ¼ö ÀÖÀ¸¸é ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿©(¶Ñ²±À» ²À ´Ý¾Æ) º¸°üÇÑ´Ù. 
3) ¿À¿ë(À߸ø »ç¿ë)À» ¸·°í ǰÁúÀÇ º¸Á¸À» À§ÇÏ¿© ´Ù¸¥ ¿ë±â¿¡ ¹Ù²Ù¾î ³ÖÁö ¾Ê´Â´Ù.
 | 
   
  	
  
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        
				         (crotamiton; )
				        
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Camphor¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
Diphenhydramine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Crotamiton¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching.
  Dibucaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
  Diphenhydramine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
  Menthol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Menthol is classified as a calcium channel blocker. Calcium channel blockers are a class of drugs with effects on many excitable cells of the body, like the muscle of the heart, smooth muscles of the vessels or neuron cells. Calcium channel blockers work by blocking voltage-sensitive calcium channels in the heart and in the blood vessels. This prevents calcium levels from increasing as much in the cells when stimulated, leading to less contraction. 
     | 
   
  
   
    | Pharmacology | 
     
       Crotamiton¿¡ ´ëÇÑ Pharmacology Á¤º¸ Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism.
  Dibucaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dibucaine is an amide-type local anesthetic, similar to lidocaine.
  Diphenhydramine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
  Menthol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. Menthol's ability to chemically trigger cold-sensitive receptors in the skin is responsible for the well known cooling sensation that it provokes when inhalated, eaten, or applied to the skin. It should be noted that menthol does not cause an actual drop in temperature. 
     | 
   
  
   
    | Metabolism | 
    
       Crotamiton¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
  Dibucaine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)Cholinesterase
  Diphenhydramine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)Cytochrome P450 3A4 (CYP3A4) 
     | 
   
  
   
    | Protein Binding | 
    
       Crotamiton¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
  Dibucaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
  Diphenhydramine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 98 to 99%
  Menthol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available 
     | 
   
  
   
    | Half-life | 
    
       Crotamiton¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
  Dibucaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
  Diphenhydramine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-4 hours
  Menthol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available 
     | 
   
  
   
    | Absorption | 
    
       Crotamiton¿¡ ´ëÇÑ Absorption Á¤º¸ 10 % absorbed when applied locally.
  Dibucaine¿¡ ´ëÇÑ Absorption Á¤º¸ In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
  Diphenhydramine¿¡ ´ëÇÑ Absorption Á¤º¸ Quickly absorbed with maximum activity occurring in approximately one hour.
  Menthol¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available 
     | 
   
  
   
    | Pharmacokinetics | 
    
       MentholÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ¼Ò½Ç : Èí¼öµÈ ¾à¹°Àº glucuronide Æ÷ÇÕü·Î¼ ¼Òº¯ ¹× ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
  
 Dibucaine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ÀÛ¿ë¹ßÇö½Ã°£ : 15ºÐ À̳»
 
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 2-4 ½Ã°£
 
 - Èí¼ö : ¼Õ»óµÇÁö ¾ÊÀº ÇǺο¡ Àû¿ë½Ã Èí¼ö´Â ¸Å¿ì ÀûÁö¸¸, Á¡¸·À̳ª ¼Õ»óµÈ ÇǺηκÎÅÍ´Â Àß Èí¼öµÈ´Ù.
   
 DiphenhydramineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÃÖ°í ÁøÁ¤ È¿°ú : 1-3 ½Ã°£
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 4-7 ½Ã°£
	
 - Èí¼ö : ÃÊȸÅë°úÈ¿°ú°¡ ÀÖ¾î¼ 40 - 60 % Á¤µµ°¡ Àü½Å¼øÈ¯À¸·Î µé¾î°¨
	
 - ´ë»ç : ´ëºÎºÐ °£´ë»ç, ÀϺδ Æó¿Í ½ÅÀå¿¡¼µµ ´ë»ç
	
 - ´Ü¹é°áÇÕ : 78%
	
 - ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£
 
  
     | 
   
  
   
    | Biotransformation | 
    
       Crotamiton¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
  Dibucaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic.
  Diphenhydramine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic and renal 
     | 
   
  
   
    | Toxicity | 
    
       Crotamiton¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
  Dibucaine¿¡ ´ëÇÑ Toxicity Á¤º¸ Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
  Diphenhydramine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.
  Menthol¿¡ ´ëÇÑ Toxicity Á¤º¸ Menthol, DL: ORAL (LD50): Acute: 2900 mg/kg [Rat], 3100 mg/kg [Mouse]. DERMAL (LD50): Acute: 5001 mg/kg [Rabbit]. 
     | 
   
  
   
    | Drug Interactions | 
    
       Crotamiton¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acetohexamide	The beta-blocker decreases the symptoms of hypoglycemiaChlorpropamide	The beta-blocker decreases the symptoms of hypoglycemiaCimetidine	Cimetidine increases the effect of the beta-blockerClonidine	Increased hypertension when clonidine stoppedDisopyramide	The beta-blocker increases toxicity of disopyramideGliclazide	The beta-blocker decreases the symptoms of hypoglycemiaGlipizide	The beta-blocker decreases the symptoms of hypoglycemiaGlisoxepide	The beta-blocker decreases the symptoms of hypoglycemiaGlibenclamide	The beta-blocker decreases the symptoms of hypoglycemiaGlycodiazine	The beta-blocker decreases the symptoms of hypoglycemiaInsulin	The beta-blocker decreases the symptoms of hypoglycemiaLidocaine	The beta-blocker increases the effect and toxicity of lidocainePropafenone	Propafenone increases the effect of beta-blockerRepaglinide	The beta-blocker decreases the symptoms of hypoglycemiaRifampin	Rifampin decreases the effect of the metabolized beta-blockerTelithromycin	Telithromycin may possibly increase metoprolol effectTolazamide	The beta-blocker decreases the symptoms of hypoglycemiaTolbutamide	The beta-blocker decreases the symptoms of hypoglycemiaAmobarbital	The barbiturate decreases the effect of metabolized beta-blockerAprobarbital	The barbiturate decreases the effect of metabolized beta-blockerButalbital	The barbiturate decreases the effect of metabolized beta-blockerButabarbital	The barbiturate decreases the effect of metabolized beta-blockerButethal	The barbiturate decreases the effect of metabolized beta-blockerDihydroquinidine barbiturate	The barbiturate decreases the effect of metabolized beta-blockerHeptabarbital	The barbiturate decreases the effect of metabolized beta-blockerHexobarbital	The barbiturate decreases the effect of metabolized beta-blockerMethohexital	The barbiturate decreases the effect of metabolized beta-blockerMethylphenobarbital	The barbiturate decreases the effect of metabolized beta-blockerPentobarbital	The barbiturate decreases the effect of metabolized beta-blockerPhenobarbital	The barbiturate decreases the effect of metabolized beta-blockerPrimidone	The barbiturate decreases the effect of metabolized beta-blockerQuinidine barbiturate	The barbiturate decreases the effect of metabolized beta-blockerSecobarbital	The barbiturate decreases the effect of metabolized beta-blockerTalbutal	The barbiturate decreases the effect of metabolized beta-blockerCitalopram	The SSRI increases the effect of the beta-blockerEscitalopram	The SSRI increases the effect of the beta-blockerFluoxetine	The SSRI increases the effect of the beta-blockerSertraline	The SSRI increases the effect of the beta-blockerParoxetine	The SSRI increases the effect of the beta-blockerDihydroergotamine	Ischemia with risk of gangreneDihydroergotoxine	Ischemia with risk of gangreneErgonovine	Ischemia with risk of gangreneErgotamine	Ischemia with risk of gangreneMethysergide	Ischemia with risk of gangreneVerapamil	Increased effect of both drugsHydralazine	Increased effect of both drugsDiltiazem	Increased risk of bradycardiaEpinephrine	Hypertension, then bradycardiaFenoterol	AntagonismFormoterol	AntagonismIsoproterenol	AntagonismOrciprenaline	AntagonismPirbuterol	AntagonismPrazosin	Risk of hypotension at the beginning of therapyProcaterol	AntagonismSalbutamol	AntagonismSalmeterol	AntagonismTerbutaline	AntagonismIbuprofen	Risk of inhibition of renal prostaglandinsIndomethacin	Risk of inhibition of renal prostaglandinsPiroxicam	Risk of inhibition of renal prostaglandins
  Dibucaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Methotrexate	The NSAID increases the effect and toxicity of methotrexateLithium	The NSAID increases serum levels of lithiumAcenocoumarol	The NSAID increases the anticoagulant effect
  Diphenhydramine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Atomoxetine	The CYP2D6 inhibitor could increases the effect and toxicity of atomoxetineDonepezil	Possible antagonism of actionGalantamine	Possible antagonism of actionMesoridazine	Increased risk of cardiotoxicity and arrhythmiasRivastigmine	Possible antagonism of actionThioridazine	Increased risk of cardiotoxicity and arrhythmias
  Menthol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Crotamiton¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
  Diphenhydramine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Crotamiton¿¡ ´ëÇÑ Description Á¤º¸ Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
  Dibucaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
  Diphenhydramine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
  Menthol¿¡ ´ëÇÑ Description Á¤º¸ Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. It is a waxy, crystalline substance, clear or white in color, which is solid at room temperature and melts slightly above. The main form of menthol occurring in nature is (-)-menthol, which is assigned the (1R,2S,5R) configuration. Menthol has local anesthetic and counterirritant qualities, and it is widely used to relieve minor throat irritation. 
     | 
   
  
   
    | Dosage Form | 
    
       Crotamiton¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream	Topical
  Dibucaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Ointment	Rectal
  Diphenhydramine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule	OralCream	TopicalElixir	OralLiquid	IntramuscularLiquid	IntravenousLiquid	OralLozenge	OralStrip	OralSyrup	OralTablet	OralTablet, chewable	Oral
  Menthol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream	TopicalGel	TopicalLiquid	NasalLiquid	OralLiquid	TopicalLozenge	OralOintment	TopicalPatch	TopicalPowder	TopicalSolution / drops	OralSpray	Topical 
     | 
   
  
   
    | Drug Category | 
    
       Crotamiton¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiparasitic AgentsAntipruriticsPesticidesScabicides
  Dibucaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anesthetics, Local
  Diphenhydramine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Allergic AgentsAntidyskineticsAntiemeticsAntiparkinson AgentsAntipruriticsAntitussivesEthanolamine DerivativesHistamine H1 AntagonistsHypnotics and Sedatives
  Menthol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antipruritics 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Crotamiton¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(C(=O)C=CC)C1=CC=CC=C1C
  Dibucaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
  Diphenhydramine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
  Menthol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)C1CCC(C)CC1O 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Crotamiton¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(C(=O)\C=C\C)C1=CC=CC=C1C
  Dibucaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
  Diphenhydramine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
  Menthol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O 
     | 
   
  
   
    | InChI Identifier | 
    
       Crotamiton¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3
  Dibucaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)/f/h21H
  Diphenhydramine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
  Menthol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Crotamiton¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-ethyl-N-(2-methylphenyl)but-2-enamide
  Dibucaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide
  Diphenhydramine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[di(phenyl)methoxy]-N,N-dimethylethanamine
  Menthol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-04-04
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
 |  
             
             | 
         
         
         | 
         |